{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cui CS"],"funding":["National Health and Medical Research Council"],"pagination":["41-51"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8762733"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["The complement C5a receptor 1 (C5aR1) has been studied as a potential therapeutic target for autoimmune and inflammatory diseases, with several drug candidates identified. Understanding the pharmacokinetics and pharmacodynamics of a drug candidate is a crucial preclinical step that allows for a greater understanding of a compound's in vivo biodistribution and target engagement to assist in clinical dose selection and dosing frequency. However, few in vivo pharmacodynamic methods have been described for C5a inhibitors. In this study, we, therefore, developed a complete in vivo pharmacodynamic assay in mice and applied this method to the peptide-based C5aR1 antagonists PMX53 and JPE-1375. Intravenous administration of recombinant mouse C5a induced rapid neutrophil mobilization and plasma TNF"],"journal":["ACS pharmacology & translational science"],"pubmed_title":["In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy."],"pmcid":["PMC8762733"],"funding_grant_id":["APP1118881"],"pubmed_authors":["Kumar V","Lee JD","Gorman DM","Woodruff TM","Clark RJ","Cui CS"],"additional_accession":[]},"is_claimable":false,"name":"In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy.","description":"The complement C5a receptor 1 (C5aR1) has been studied as a potential therapeutic target for autoimmune and inflammatory diseases, with several drug candidates identified. Understanding the pharmacokinetics and pharmacodynamics of a drug candidate is a crucial preclinical step that allows for a greater understanding of a compound's in vivo biodistribution and target engagement to assist in clinical dose selection and dosing frequency. However, few in vivo pharmacodynamic methods have been described for C5a inhibitors. In this study, we, therefore, developed a complete in vivo pharmacodynamic assay in mice and applied this method to the peptide-based C5aR1 antagonists PMX53 and JPE-1375. Intravenous administration of recombinant mouse C5a induced rapid neutrophil mobilization and plasma TNF","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-05T08:47:38.318Z","creation":"2025-04-05T08:47:38.318Z"},"accession":"S-EPMC8762733","cross_references":{"pubmed":["35059568"],"doi":["10.1021/acsptsci.1c00227"]}}